Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2005
08/25/2005US20050187211 N-arylsalkyl-carboxamide compositions and methods
08/25/2005US20050187210 Method for treating severe heart failure and medicament therefor
08/25/2005US20050187209 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
08/25/2005US20050187206 Novel crystalline forms of temozolomide
08/25/2005US20050187205 Pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
08/25/2005US20050187204 Effective amounts of an 3-hydroxy-3-methylglutaryl/coenzyme A reductase (HMG-COA reductase) inhibitor and bile acids; prophaylaxis and treatment of diseases caused by high blood lipid levels, e.g. hypercholesterolemia or atherosclerosis; anticholesterol agents; administered concurrently or separately
08/25/2005US20050187203 combination of a pyrazolo(1,5-a)pyridine compound such as ibudilast with a corticosteroid; treating immunoinflammatory disorders e.g. rheumatoid arthritis, ulcerative colitis
08/25/2005US20050187201 Use of 2-methylene-19-nor-20(S)-1alpha,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
08/25/2005US20050187200 Methods and reagents for the treatment of inflammatory disorders
08/25/2005US20050187199 applying a composition of an NSAID to a mucous membrane of a patient at risk for developing symptoms of Herpes simplex, Herpes zoster, or allergy; may also contain an anti-irritant such as a non-nutritive sweetener
08/25/2005US20050187196 administering an effective amount of a GABAB receptor antagonist 3-aminopropyl-(n-butyl)-phosphinic acid (ABPA); for patients who do not respond to stimulants, cannot tolerate their side effects such as nausea and insomnia, or cannot use them because of their abuse potential
08/25/2005US20050187194 fructose 1,6-bisphosphatase (FBPase) inhibitors for diabetic complications, hyperlipidemia, hypertension, arteriosclerosis, macroangiopathy; 2-amino-5-isobutyl-4-{2-[5-(N,N'-bis((S)-1-ethoxycarbonyl)ethyl)phosphonamido]furanyl}thiazole
08/25/2005US20050187193 Reducing plasma levels of apo B and LDL cholesterol and in decreasing plasma total cholesterol; restenosis following angioplasty; atherosclerosis, hypercholesterolemia; use with other drugs such as statins; e.g. diethyl alpha-(3,5-dimethoxy-4-hydroxyphenyl)-beta-(N-(3-pyridyl)-amino)-vinylphosphonate
08/25/2005US20050187192 use of 3-alkylamido-2-alkoxypropyl-1-phosphocholine compounds such as 3-dodecanamido-2-ethoxypropyl-1-phosphocholine; Severe Acute Respiratory syndrome (SARS-CoV) infections
08/25/2005US20050187191 use of 3-alkylamido-2-alkoxypropyl-1-phosphocholine compounds such as 3-dodecanamido-2-ethoxypropyl-1-phosphocholine
08/25/2005US20050187190 Autoinducer-2 compounds as immunomodulatory agents
08/25/2005US20050187189 Artemisinins with improved stability and bioavailability for therapeutic drug development and application
08/25/2005US20050187188 Methods for the treatment of a traumatic central nervous system injury
08/25/2005US20050187187 obtained by sulfatation of a quaternary ammonium salt of chondroitin sulfate in organic medium by means of a complex of sulfuric anhydride with an organic base such as pyridine or trimethylamine, followed by carboxyl-reduction by means of a carbodiimide derivative; matrix metalloproteinase inhibitor
08/25/2005US20050187186 useful for the treatment of cancer and other hyperproliferative disorders; a sphingolipid; lactic acid; and optionally a stabilizing agent; emulsion
08/25/2005US20050187185 for tautening skin, in particular for reducing the size of wrinkles in the facial region in a long-lasting manner; comprising crosslinked or uncrosslinked hyaluronic acid associated with heparin
08/25/2005US20050187184 Administering CCI-779 [or 42-O-(2-hydroxy)ethyl rapamycin] and an aromatase inhibitor such as letrozole; therapy of neoplasms; useful in the treatment of renal cancer, soft tissue cancer, breast cancer, neuroendocrine tumor of the lung, cervical cancer, uterine cancer, head and neck cancer
08/25/2005US20050187183 Use of amphiphilic nucleoside phosphonoformic acid derivatives for the treatment of viral infectious diseases
08/25/2005US20050187182 Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
08/25/2005US20050187181 Use of purine nucleosides to stimulate Na/K ATPase and to treat or prevent shock
08/25/2005US20050187179 treatment of tumors which have increased Notch expression; administration of either Notch antisense oligonucleotides or monoclonal antibodies directed to Notch along with cell differentiating agent
08/25/2005US20050187173 A method of delaying the onset of diabetes
08/25/2005US20050187172 Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia
08/25/2005US20050187171 Glycomimetic antagonists for both E-and P-selectins
08/25/2005US20050187170 a mycophenolate or ribavirin; Tagetin (reg); effective treatment for a viral infection; Hepatitis C
08/25/2005US20050187169 6-11 Bicyclic erythromycin derivatives
08/25/2005US20050187168 Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
08/25/2005US20050187167 Polyene polyketides, processes for their production and their use as a pharmaceutical
08/25/2005US20050187166 C-nitroso compounds and use thereof
08/25/2005US20050187157 Pharmaceutical compositions based on anticholinergics and pegsunercept
08/25/2005US20050187149 Antitumor agent
08/25/2005US20050187148 Antitumor agent
08/25/2005US20050187147 Compositions and methods for increasing drug efficiency
08/25/2005US20050187145 template-fixed beta -hairpin peptidomimetics incorporating a template-fixed chain of 7 or 11 alpha -amino acid residues which, depending on their position in the chain, are Gly, or Pro, or of certain types; inhibitors of various serine proteases such as trypsin, human cathepsin G, and thrombin
08/25/2005US20050187144 Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
08/25/2005US20050187140 Implanting a spinal implant by infiltrating a tissue of a host near the implant with an antifibrotic agent, and/or an antiinfective agent and/or a polymer; prevention of surgical adhesions
08/25/2005US20050186650 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
08/25/2005US20050186638 Detecting modulators of brain membrane protein; obtained membrane protein incubated with ligand and labeled compound, measure level of binding
08/25/2005US20050186571 Diagnosis and prevention of cancer cell invasion
08/25/2005US20050186567 Antisense modulation of peroxisome proliferator-activated receptor gamma expression
08/25/2005US20050186559 Identifying Amyloid precurser protein lowering agents; non-steroidal anti-inflammatory drug (NSAID); Alzheimer's disease
08/25/2005US20050186526 Methods and systems for enabling and stabilizing tooth movement
08/25/2005US20050186295 Constituent of the aqueous extract from the radix glycyrrhizae inflatae: treatment of skin disorders
08/25/2005US20050186294 Manual clitoral sensitizing mixture having a cooling agent chosen from oils of peppermint, cornmint, eucalyptus, camphor, citronella and cinnamon; vasodilation
08/25/2005US20050186289 Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
08/25/2005US20050186288 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
08/25/2005US20050186284 Pharmaceutically active ingredient and a starch, wherein pharmaceutically active ingredient is packaged by starch to form a microparticle; pleasant taste and acceptable disintegration speed in oral cavity; possesses sufficient mechanical strength so as to protect preparation during compression molding
08/25/2005US20050186281 Dissolved phenolic antimicrobial agent is chloroxylenol, 2,4,*-trichloro-2*-hydroxydiphenyl ether, benzylalkonium chloride, or 4-chloro-3,5-dimethylphenol; glycol, glycerin, neutralizing agent, preservative, acrylic polymer, polysaccharide polymer, and/or deionized water; surfactant- and alcohol-free
08/25/2005US20050186279 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
08/25/2005US20050186278 Gastroprotected formulations containing alph-amylase inhibitors
08/25/2005US20050186277 Novel formulations for the administration of fluoxetine
08/25/2005US20050186276 Pharmaceutical formulations
08/25/2005US20050186274 Multilayer tablet
08/25/2005US20050186272 Pharmaceutical composition for oral application and method for preparing thereof
08/25/2005US20050186270 Reduced lactose excipient content; replaced with cellulose; disintegrants of starch, sodium starch glycolate, croscarmellose sodium or calcium and/or crosslinked polyvinypyrrolidone(crospovidone); free of magnesium stearate, citric acid, ascorbic acid, and butylated hydroxyanisole
08/25/2005US20050186269 Stabilized feverfew formulations
08/25/2005US20050186267 Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
08/25/2005US20050186266 Chlamydia antigens and corresponding DNA fragments and uses thereof
08/25/2005US20050186265 Negatively charged first lipid; barium, calcium, zinc, magnesium and/or cation; carbohydrates, vitamins, minerals, polynucleotides, polypeptides, lipids, flavors and drugs; particle sizes; storage stability, oxidation resistance, dimensional stability;
08/25/2005US20050186263 PH-sensitive polymeric micelles for drug delivery
08/25/2005US20050186262 Adhesive matrix reservoir affixed to side of backing layer and is comprised of felodipine or isradipine and fatty acid permeation enhancer; solvent-free; hypotensive agents; photosensitive drugs
08/25/2005US20050186261 Compositions and methods for treating contracture
08/25/2005US20050186259 Method for providing antimicrobial composite yarns, composite fabrics and articles made therefrom
08/25/2005US20050186257 Forming a mixture comprising a water insoluble active ingredient such as caffeine and film-forming ingredients, coating onto a substrate; drying; topical or oral administering by applying to a moist area of individual to release active ingredient; flavor or drug delivery
08/25/2005US20050186252 Chewable; organoleptic; partially hydrolyzed guar gum; no need for ingestion aid; compression molding
08/25/2005US20050186251 Resorbable polymer and N-methyl-2-pyrrolidone imparts osteogenic properties
08/25/2005US20050186250 Metallic structures incorporating bioactive materials and methods for creating the same
08/25/2005US20050186247 Such as silk, which induce a fibrotic response in the surrounding tissue such that the device is anchored in situ and its performance is enhanced; prosthetic joint for example
08/25/2005US20050186244 Polymer compositions and methods for their use
08/25/2005US20050186230 Injectable oil-in-water emulsion; less vein irritation; antineoplastic agents
08/25/2005US20050186229 Pleasant-tasting aqueous liquid composition of prednisolone sodium phosphate
08/25/2005US20050186221 Mixing reducing agent such as sodium thiosulfate with water, which may include oxidizing water sanitizers, and treating livestock
08/25/2005US20050186208 Anti-neoplastic composition of adrenocorticosteroides, progestins, estrogens, antiestrogen, androgens; breast cancer, colorectal cancer, rectal cancer, non-small cell lung cancer, non-Hodgkins lymphoma (NHL), renal cell cancer, prostate cancer, liver cancer, pancreatic cancer, soft-tissue sarcoma
08/25/2005US20050186205 Administering unlabelled anti-CD20 antibody that binds to the CD20 antigen present on lymphoma cells; a second treatment of cyclophosphamide, doxorubicin, vincristine or prednisone
08/25/2005US20050186198 Serine protease inhibitors
08/25/2005US20050186196 Orally or parenterally administrable; comprises L-carnitine inner salt, acetyl L-carnitine inner salt, alpha -lipoic acid, coenzyme Q10, Vitamin E and selenomethionine; for reducing oxidative stress
08/25/2005US20050186195 Structural or functional components of the creatine kinase/ phosphocreatine system sufficient to prevent, reduce or ameliorate skin damage or skin aging; psoriasis
08/25/2005US20050186194 Structural or functional components of the creatine kinase/ phosphocreatine system sufficient to prevent, reduce or ameliorate skin damage or skin aging; psoriasis
08/25/2005US20050186188 Compositions containing probiotics and polysaccharides and methods of use
08/25/2005US20050186187 Altering the expression levels of a protein; modulating the activity of secretory leukocyte protease inhibitor (SLPI), CD53, or Transferrin-1 in a cell and culturing the cells
08/25/2005US20050186175 such as etanercept and said ester anticholinergic e.g. scopine 2,2-diphenylpropionic acid ester methobromide; treating inflammatory or obstructive respiratory system disorders such as asthma or chronic obstructive pulmonary disease (COPD); inhalants
08/25/2005US20050186174 Compositions comprising two different populations of polymer-active agent conjugates
08/25/2005US20050186173 Biocidal siloxane coating material containing N-halogenated amine and amide functional groups
08/25/2005US20050186169 Tetrapolymer of methacrylic acid, methyl methacrylate, butyl acrylate and C16-C20 alkyl (meth)acrylates; free of sunscreen agents; treatment of wrinkled skin
08/25/2005US20050186161 Comprises neticonazole and a basic substance; high permeability into nail and also has high efficacy
08/25/2005US20050186158 Use of creatine or creatine compounds for skin preservation
08/25/2005US20050186156 Dapsone protectants that reduce the risk of skin damage; sunscreen
08/25/2005US20050186145 such as etanercept and said ester anticholinergic e.g. scopine 9-methyl-fluorene-9-carboxylate methobromide; treating inflammatory or obstructive respiratory system disorders such as asthma or chronic obstructive pulmonary disease (COPD); inhalants
08/25/2005US20050186144 Treatment methods
08/25/2005US20050186139 Heat pressing a mixture of an active ingredient with abuse potential, a high strength polymer, and a wax into a controlled release dosage form; cannot be dispersed or even dissolved in such a manner that it may safely be administered parenterally, in particular intravenously
08/25/2005US20050186135 therapy for tumors, lesions, cancer by in situ supplying peroxide and hypochlorite; drug delivery
08/25/2005US20050185069 Still camera with audio decoding and coding, a printable audio format, and method
08/25/2005US20050183731 Polymer compositions and methods for their use
08/25/2005DE29924789U1 New, stable crystalline polymorph (form III) of the diuretic torasemide, by controlled acidification of alkaline solutions, has more rapid dissolution than form I
08/25/2005DE19833476B4 Genetisch modifizierte CD34-Negative, adhärent wachsende hämatopoetische Stammzellen und deren Verwendung in der Gentherapie Genetically modified CD34-negative adherently growing haematopoietic stem cells and their use in gene therapy
1 ... 4567 4568 4569 4570 4571 4572 4573 4574 4575 4576 4577 4578 4579 4580 4581 4582 4583 4584 4585 4586 4587 ... 7860